These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20048079)

  • 1. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
    Wang L; Ellsworth KA; Moon I; Pelleymounter LL; Eckloff BW; Martin YN; Fridley BL; Jenkins GD; Batzler A; Suman VJ; Ravi S; Dixon JM; Miller WR; Wieben ED; Buzdar A; Weinshilboum RM; Ingle JN
    Cancer Res; 2010 Jan; 70(1):319-28. PubMed ID: 20048079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women.
    Straume AH; Knappskog S; Lønning PE
    J Steroid Biochem Mol Biol; 2012 Jan; 128(1-2):69-75. PubMed ID: 21939764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
    Cairns J; Ingle JN; Dudenkov TM; Kalari KR; Carlson EE; Na J; Buzdar AU; Robson ME; Ellis MJ; Goss PE; Shepherd LE; Goodnature B; Goetz MP; Weinshilboum RM; Li H; Bari MG; Wang L
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32701512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
    Colomer R; Monzo M; Tusquets I; Rifa J; Baena JM; Barnadas A; Calvo L; Carabantes F; Crespo C; Muñoz M; Llombart A; Plazaola A; Artells R; Gilabert M; Lloveras B; Alba E
    Clin Cancer Res; 2008 Feb; 14(3):811-6. PubMed ID: 18245543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
    Lunardi G; Piccioli P; Bruzzi P; Notaro R; Lastraioli S; Serra M; Marroni P; Bighin C; Mansutti M; Puglisi F; Porpiglia M; Ponzone R; Bisagni G; Garrone O; Cavazzini G; Clavarezza M; Del Mastro L
    Breast Cancer Res Treat; 2013 Jan; 137(1):167-74. PubMed ID: 23129173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients.
    Agarwal VR; Bulun SE; Leitch M; Rohrich R; Simpson ER
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3843-9. PubMed ID: 8923826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
    Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms associated with circulating sex hormone levels in postmenopausal women.
    Dunning AM; Dowsett M; Healey CS; Tee L; Luben RN; Folkerd E; Novik KL; Kelemen L; Ogata S; Pharoah PD; Easton DF; Day NE; Ponder BA
    J Natl Cancer Inst; 2004 Jun; 96(12):936-45. PubMed ID: 15199113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
    Artigalás O; Vanni T; Hutz MH; Ashton-Prolla P; Schwartz IV
    BMC Med; 2015 Jun; 13():139. PubMed ID: 26067721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
    Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
    Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.
    Haiman CA; Hankinson SE; Spiegelman D; De Vivo I; Colditz GA; Willett WC; Speizer FE; Hunter DJ
    Int J Cancer; 2000 Jul; 87(2):204-10. PubMed ID: 10861475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
    Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
    Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
    Napoli N; Rastelli A; Ma C; Yarramaneni J; Vattikutti S; Moskowitz G; Giri T; Mueller C; Kulkarny V; Qualls C; Ellis M; Armamento-Villareal R
    Bone; 2013 Aug; 55(2):309-14. PubMed ID: 23643682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
    Bacci M; Giannoni E; Fearns A; Ribas R; Gao Q; Taddei ML; Pintus G; Dowsett M; Isacke CM; Martin LA; Chiarugi P; Morandi A
    Cancer Res; 2016 Mar; 76(6):1615-26. PubMed ID: 26795347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
    López-Knowles E; Wilkerson PM; Ribas R; Anderson H; Mackay A; Ghazoui Z; Rani A; Osin P; Nerurkar A; Renshaw L; Larionov A; Miller WR; Dixon JM; Reis-Filho JS; Dunbier AK; Martin LA; Dowsett M
    Breast Cancer Res; 2015 Mar; 17(1):35. PubMed ID: 25888249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
    Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
    BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
    Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
    Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
    Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
    Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer.
    Díaz-Cruz ES; Brueggemeier RW
    Anticancer Agents Med Chem; 2006 May; 6(3):221-32. PubMed ID: 16712450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.